RecruitMe Clinical Trial

SYROS: SY-1365-101: A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors
Study of SY-1365 in Adult Patients with Advanced Solid Tumors
Sponsor:Syros Pharmaceuticals, Inc.
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAR9115
U.S. Government ID:NCT03134638
Contact: Reena Vattakalam: 212-342-6895 /
Additional Study Information:

SY-1365 is an investigational drug that stops the function of a protein known as CDK7. Previous workhas shown that CDK7 is necessary for some cancers to grow. Therefore, SY-1365 could be used to slow down the growth of cancer. This research study is being done to understand the highest tolerated dose of SY-1365, and to assess the safety of SY-1365 in patients with advanced solid tumors where standard therapies are no longer effective or do not exist. "Investigational" means that SY-1365 has not been approved by the United States Food and Drug Administration (FDA). This study will have two parts, the first part will include a phase where the dose of the study drug is increased from one patient to another, to determine what the highest tolerated dose is, and will also study the safety of SY-1365. The second part of this study will further study the safety and effect on your cancer of SY-1365 alone and in combination with carboplatin or fulvestrant at a dose determined during part 1. Carboplatin has been approved by the FDA for use in women with ovarian cancer and fulvestrant has been approved by the FDA for women with breast cancer. Their use in combination with SY-1365 is considered investigational.

Do You Qualify?
Have you been diagnosed with a solid tumor for which no standard measures exist or are no longer effective?YesNo
Have you been diagnosed with ovarian cancer (including fallopian tube cancer and/orprimary peritoneal cancer)?YesNo
You may be eligible for this study

Place Holder

Who Can I Contact?
For more information, please contact:

Reena Vattakalam